Amphastar Director Sells 16,679 Shares for $441,800 | The Motley Fool

Floyd Petersen, director of Amphastar Pharmaceuticals ( AMPH 1.06%), exercised 16,679 options for common stock and immediately sold all resulting shares in a transaction valued at $441,836.72, as disclosed in a SEC Form 4 filing . Transaction summary Metric Value Shares sold 16,679 Transaction value ~$441,800 Post-transaction shares 75,531 Post-transaction value (direct ownership) ~$2 million Transaction value based on SEC Form 4 weighted average purchase price ($26.49); post-transaction value based on Nov. 13, 2025 market close ($26.37). NASDAQ: AMPH Key Data Points Key questions How does the size of this transaction compare to Petersen's historical selling activity? The sale of 16,679 shares on November 13, 2025, is materially larger than the historical median sell-only transaction of 500 shares. What is the derivative context of this transaction? All 16,679 shares sold originated from the exercise of fully vested stock options, with immediate disposition in the open market. How does the transaction value relate to Petersen Floyd F.'s remaining direct ownership? Following the sale, Petersen Floyd F. retains 75,531 shares with an approximate market value of $2.0 million as of November 13, 2025, reflecting a 4% reduction in direct holdings since May 2024. What was the market context at the time of the sale? Shares were priced at around $26.49 per share for the transaction, with the stock closing at $26.37 on November 13, 2025. Over the prior 12 months, the stock declined by 42% as of the transaction date. Company overview Metric Value Price (as of market close 11/13/25) $26.49 Market capitalization $1.20 billion Revenue (TTM) $723.31 million Net income (TTM) $111.63 million * 1-year performance is calculated using November 13th, 2025 as the reference date. Company snapshot Offers a diversified portfolio of injectable, inhalation, and intranasal pharmaceutical products, including Primatene Mist, Enoxaparin, Naloxone, Glucagon, and specialty APIs. Generates revenue through the development, manufacturing, and sale of both generic and proprietary drugs, with a focus on specialty and emergency-use medications. Serves hospitals, care facilities, alternate care sites, clinics, and physicians, primarily targeting the U.S. China, and France markets. Amphastar Pharmaceuticals, Inc. is a mid-cap biopharmaceutical company specializing in specialty and generic injectable and inhalation products. The company leverages a vertically integrated model, with in-house API production and a diverse product pipeline, to address critical needs in acute care and emergency medicine. Its strategic focus on both proprietary and generic products positions it to capture demand from institutional healthcare providers and respond to evolving market opportunities. Foolish take Floyd Petersen's share sale on Nov. 13 was an exercise and sell move in which the executive exercised his right to purchase 16,679 shares at $16.69 a piece and sold the shares immediately on the open market for $26.49 a piece, a total sale value of $441,800. Amphastar Pharmaceuticals stock was down 42% on the year on the day of the transaction, compared to a 14% total return for the S&P 500 . The stock is up 5% over the last month as of Dec. 23, after the company announced the FDA had approved...

Preview: ~500 words